Investigational Drug Information for Filgotinib
✉ Email this page to a colleague
What is the drug development status for Filgotinib?
Filgotinib is an investigational drug.
There have been 35 clinical trials for Filgotinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 12th 2021.
The most common disease conditions in clinical trials are Arthritis, Arthritis, Rheumatoid, and Colitis, Ulcerative. The leading clinical trial sponsors are Galapagos NV, Gilead Sciences, and Leiden University Medical Center.
There are one hundred and thirty-two US patents protecting this investigational drug and zero international patents.
Summary for Filgotinib
| US Patents | 132 |
| International Patents | 1,750 |
| US Patent Applications | 516 |
| WIPO Patent Applications | 468 |
| Japanese Patent Applications | 156 |
| Clinical Trial Progress | Phase 3 (2021-05-12) |
| Vendors | 65 |
Recent Clinical Trials for Filgotinib
| Title | Sponsor | Phase |
|---|---|---|
| Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects | Galapagos NV | Phase 1 |
| A Phase 3 Program Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis | Galapagos NV | Phase 3 |
| Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis | Galapagos NV | Phase 4 |
Clinical Trial Summary for Filgotinib
Top disease conditions for Filgotinib
Top clinical trial sponsors for Filgotinib
US Patents for Filgotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Filgotinib | ⤷ Subscribe | Methods for the treatment of HER2 amplified cancer | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Subscribe |
| Filgotinib | ⤷ Subscribe | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (Atlanta, GA) | ⤷ Subscribe |
| Filgotinib | ⤷ Subscribe | Compounds | CHIESI FARMACEUTICI S.P.A. (Parma, IT) | ⤷ Subscribe |
| Filgotinib | ⤷ Subscribe | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Subscribe |
| Filgotinib | ⤷ Subscribe | Kinase inhibitors | Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB) | ⤷ Subscribe |
| Filgotinib | ⤷ Subscribe | Imidazopyridazine compounds | Pfizer Inc. (New York, NY) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Filgotinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Filgotinib | Canada | CA2920534 | 2033-08-12 | ⤷ Subscribe |
| Filgotinib | European Patent Office | EP3033079 | 2033-08-12 | ⤷ Subscribe |
| Filgotinib | Spain | ES2709509 | 2033-08-12 | ⤷ Subscribe |
| Filgotinib | Japan | JP2016528251 | 2033-08-12 | ⤷ Subscribe |
| Filgotinib | Japan | JP2019031546 | 2033-08-12 | ⤷ Subscribe |
| Filgotinib | Japan | JP2021008475 | 2033-08-12 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
